Format

Send to

Choose Destination
Br J Haematol. 2020 Feb 5. doi: 10.1111/bjh.16433. [Epub ahead of print]

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK-NUP214 shows a favourable outcome when performed in first complete remission.

Author information

1
Hematology Department, Hospital Clínic of Barcelona, Barcelona, Spain.
2
IDIBAPS, Josep Carreras Leukemia Research Institute, Barcelona, Spain.
3
EBMT Paris Study Office, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France.
4
University Hospital Gasthuisberg, Leuven, Belgium.
5
King Faisal Specialist Hospital & Research Centre Oncology, Riyadh, Saudi Arabia.
6
University Hospital Hematology, Basel, Switzerland.
7
Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
8
Department of Internal Medicine, Hematology/Oncology, University Hospital, Maastricht, The Netherlands.
9
Division of Hematology, Hospital Saint Louis & University Paris, Paris, France.
10
Radbud University Medical Centre, Nijmegen, The Netherlands.
11
Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
12
Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
13
Hôpital Edouard Herriot, Lyon, France.
14
Hematology Department, Hospital de la Santa Creu i Sant Pau, IIB-Santpau and Josep Carreras Leukemia Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
15
Department of Hematology, Hospital Saint Antoine, Paris, France.
16
Medicine Department, University of Barcelona, Barcelona, Spain.
17
Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Abstract

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1.

KEYWORDS:

AML; DEK-NUP214; allo-SCT; prognosis; t(6;9) AML

PMID:
32020596
DOI:
10.1111/bjh.16433

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center